Watrium has entered into an agreement to sell sections in Fondsbygget at Aker Brygge in Oslo to Norwegian Property. The sections comprise approximately 3,200 square meters, mainly retail space on the ground floor. The closing of the transaction will take place in September 2016, and the agreed purchase price is NOK 204 million net of...
Watrium invests to become a shareholder of Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer. Its leading product is UV1, a therapeutic cancer vaccine directed against human telomerase. Watrium’s Kristin Wilhelmsen also joins the company’s board of directors. For more information, see the Ultimovacs website.
Watrium invests in a 20 percent ownership share in Fornebu Gateway AS, which owns two ultra-modern office buildings at Fornebu outside Oslo. The buildings have lease contract durations of around 12 years. For further details, see the announcement from Aker ASA.
